Simulations Plus Finalizes Distributor Agreement With Korean Company
06 April 2017 - 10:30PM
Business Wire
Local sales channel should lead to further
penetration of domestic Korean pharmaceutical market
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of
modeling & simulation solutions for the pharmaceutical,
biotechnology, and chemicals industries, today announced that it
has entered into a distributor agreement in South Korea with
Quantum Bio Solutions (Q-Bio).
John DiBella, vice president for marketing and sales of
Simulations Plus, said: “We are excited to be partnering with Q-Bio
to further serve the needs of the South Korean scientific markets.
We have been hosting annual GastroPlus™ modeling & simulation
workshops at Chungnam National University in Daejeon, South Korea
since 2014, and we have been encouraged by the response to our
technology. The South Korean government has pledged nearly $9
billion to help domestic drug makers develop twenty new drugs with
the goal of being among the world’s top seven global pharmaceutical
producing countries by the year 2020. Therefore, we see this as a
most opportune time to have a local presence in South Korea to
increase awareness of Simulations Plus and our suite of offerings,
while also strengthening the relationships we have already formed
with South Korean companies and universities.”
Art Cho, Ph.D., Professor at Korea University and
President/Chief Scientific Officer at Q-Bio, added: “Q-Bio has been
searching for a business opportunity that would complement and
expand our current offerings in the field of computational drug
discovery & development. Simulations Plus is a recognized
leader in this field, and we are very happy to serve as a partner
for them. We look forward to a very fruitful relationship, as we
expect to help Simulations Plus achieve meaningful growth in the
burgeoning South Korean pharmaceutical market.”
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions. The company is a global leader focused on
improving the ways scientists use knowledge and data to predict the
properties and outcomes of pharmaceutical and biotechnology agents.
Our software is licensed to and used in the conduct of drug
research by major pharmaceutical and biotechnology companies and
regulatory agencies worldwide. Our innovations in integrating new
and existing science in medicinal chemistry, computational
chemistry, pharmaceutical science, biology, and physiology into our
software have made us the leading software provider for
physiologically based pharmacokinetic modeling and simulation. For
more information, visit our website at
www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
as filed with the U.S. Securities and Exchange Commission.
Follow us on Twitter | LinkedIn
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170406005464/en/
Simulations Plus Investor
RelationsMs. Renee Bouche,
661-723-7723renee@simulations-plus.comorHayden IRMr. Cameron Donahue,
651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2024 to May 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From May 2023 to May 2024